Argatroban anticoagulation in renal dysfunction: a literature analysis

Area of Science:

• Pharmacology
• Nephrology
• Hematology

Background:

• Argatroban is a direct thrombin inhibitor used for heparin-induced thrombocytopenia (HIT) and in antithrombin-deficient patients undergoing hemodialysis.
• Its metabolism is primarily hepatic, raising questions about its use in patients with renal dysfunction.

Purpose of the Study:

• To determine the impact of renal function on argatroban pharmacokinetics, pharmacodynamics, and therapeutic dosage in HIT patients.
• To evaluate argatroban dosing and safety during renal replacement therapy (RRT) and in adults with renal dysfunction undergoing procedures.

Main Methods:

• A literature search identified 34 publications describing 644 patients treated with argatroban.
• Data on renal function, argatroban pharmacokinetics, pharmacodynamics, and clinical outcomes were extracted and summarized.

Main Results:

• Renal dysfunction had minimal clinical effect on argatroban pharmacokinetic parameters.
• In HIT, initial doses sometimes required reduction, especially in patients with hepatic dysfunction.
• Reduced doses were needed for combined hepatic and renal dysfunction, with dose decreasing as creatinine clearance dropped.
• Argatroban was well-tolerated during RRT with minimal complications.

Conclusions:

• Argatroban is well-tolerated and provides adequate anticoagulation in patients with renal dysfunction or failure.
• It is a viable option for patients with HIT or antithrombin deficiency, where anticoagulant choices are limited.